Comparison of performance profiles of TTF1 antibodies for differential diagnosis

Adam Swalling, Douglas Henderson, Lisa Jonavicius, Sonja Klebe

    Research output: Contribution to journalMeeting Abstractpeer-review


    Thyroid transcription factor -1 (TTF1) is a useful immunohistochemical (IHC) marker for diagnosis of primary lung tumours including differential diagnosis between primary lung adenocarcinoma (AdCa) and mesothelioma (MM). Different TTF1 monoclonal antibodies (MoAbs) are available. The clone SP141 achieved the highest score in the 2014 RCPA QAP. Most published studies used the 8G7G3/1 MoAb and inconsistencies in labelling between different antibodies have been described. Our study compared the performance of 8G7G3/1 and SP141 TTF1 MoAbs in primary AdCa and squamous cell carcinoma (SCC) of lung, and MM.

    We examined IHC labelling in 83 cases of MM (17 sarcomatoid, 66 epithelioid), 13 poorly differentiated SCCs and 35 AdCas.

    All AdCas labelled with both the SP141 and 8G7G3/1 MoAbs. All MMs and SCCs were negative with 8G7G3/1, but 7/17 sarcomatoid, 0/66 epithelioid MMs and 6/13 SCCs were positive with SP141.

    TTF1 expression is useful for diagnosis of primary lung AdCas, but different antibodies have different performance profiles, which may have clinical implications and must be taken into account.
    Original languageEnglish
    Pages (from-to)S76-S77
    Number of pages2
    Issue numberSupp. 1
    Publication statusPublished - 2015
    Event39th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology - Brisbane Convention & Exhibition Centre, Brisbane, Australia
    Duration: 30 May 20141 Jun 2014


    • TTF1 antibodies
    • immunohistochemical (IHC) marker
    • differential diagnosis


    Dive into the research topics of 'Comparison of performance profiles of TTF1 antibodies for differential diagnosis'. Together they form a unique fingerprint.

    Cite this